Glycoimmunomics of human cancer: current concepts and future perspectives.
Future strategies for the treatment of human cancer require a full appreciation of the intracellular and extracellular changes that accompany neoplastic transformation. The changes may involve a variety of micro- and macro-molecules, including, but not restricted to, peptides, proteins (with sugar and/or lipid moieties), oligosaccharides, glycolipids (neutral or acidic, e.g., gangliosides), ceramides, fatty acids and other lipids. Although several therapeutic approaches have been well developed in recent years, most of the reported studies focus on proteins and peptides. Glycoantigens and lipoantigens have been neglected. Elucidation of the profiles and properties of all molecules associated with tumor progression is required to develop a successful strategy to treat human cancer. This review describes the unique immunomics of tumor-associated glycoantigens and explains why the field of glycoimmunomics may yield clinically important biomarkers and treatments for the management of human cancer.
Ravindranath
Mepur H
MH
Department of Glycoimmunotherapy, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA 90404-2302, USA. ravindranathm@jwci.org
Yesowitch
Paul
P
Sumobay
Cindy
C
Morton
Donald L
DL
D000951:Antigens, Neoplasm / Q000276:immunology*; D006017:Glycolipids; D006023:Glycoproteins; D006801:Humans; D009369:Neoplasms / Q000276:immunology* / Q000503:physiopathology*; D014411:Neoplastic Stem Cells / Q000276:immunology
D000951:Antigens, Neoplasm; D006017:Glycolipids; D006023:Glycoproteins